Re­gen­eron to buy gene ther­a­py biotech Deci­bel Ther­a­peu­tics in small $109M deal

Re­gen­eron is buy­ing Deci­bel Ther­a­peu­tics and its hear­ing loss gene ther­a­pies for a mod­est $109 mil­lion, the com­pa­nies an­nounced Wednes­day morn­ing.

Re­gen­eron and Deci­bel have been long­time col­lab­o­ra­tors in de­vel­op­ing hear­ing loss gene ther­a­pies, with their first deal dat­ing back to 2017. Deci­bel’s lead pro­gram, which is al­so its on­ly pro­gram in the clin­ic, is a gene ther­a­py for peo­ple with con­gen­i­tal hear­ing loss from mu­ta­tions in the otofer­lin gene, which re­sults in de­fec­tive sig­nal­ing from sound-sens­ing hair cells in the ear to the brain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER